Ian Mitchell McElree

494 citations
34 papers · 331 · 1 hit paper · h-index 9

Impact in

  • Surgery top 10%
    • Bladder and Urothelial Cancer Treatments
    • Urinary and Genital Oncology Studies
  • Urology top 10%
    • Urological Disorders and Treatments
    • Urinary Bladder and Prostate Research

Papers in

  • Surgery 30
    • Bladder and Urothelial Cancer Treatments 30
    • Urinary and Genital Oncology Studies 11
    • Esophageal Cancer Research and Treatment 1
  • Urology 4
    • Urological Disorders and Treatments 4
Co-authors
Michael A. O’Donnell (25 shared papers)Vignesh T. Packiam (24 shared papers)Ryan L. Steinberg (19 shared papers)Sarah L. Mott (21 shared papers)Kenneth Gerard Nepple (3 shared papers)Paul Thomas Gellhaus (3 shared papers)Mohamad Abou Chakra (6 shared papers)Neema Navai (1 shared paper)
Journals
Urologic Oncology Seminars and Original Investigations (12 papers)British Journal of Urology (5 papers)European Urology Oncology (3 papers)The Journal of Urology (3 papers)Cancers (2 papers)
Partner nations
United StatesCanadaGermany

In The Last Decade

Ian Mitchell McElree

29 papers receiving 328 citations

Ian Mitchell McElree's Hit Papers

Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non–Muscle-Invasive Bladder Cancer 2023 · 79 citations
790+1+2Years since publication255075
What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

  1. 2023 JAMA Network Open

Peers

Ian Mitchell McElree
Comparison fields: 5 of 33
  • Surgery 306
  • Urology 34
  • Hepatology 5
  • Pulmonary and Respiratory Medicine 20
  • Oncology 15
Replace Fernando Álvarez Lozano with:
Fernando Álvarez Lozano Spain
Philipp Spiegelhalder Germany
Benjamin Pradere Italy
Júlia Aumatell Spain
Viveka Ströck Sweden
Vianney Bouygues France
George Managadze Georgia
A.R. Azzouzi France
Andrea Minervini Italy
William E. Osai United States
Ian Mitchell McElree relative to Fernando Álvarez Lozano Spain Fernando Álvarez Lozano's profile →
Citations per field
00.5×2×3×4×5×
Fernando Álvarez Lozano · 1×
Citations per year

Countries citing papers authored by Ian Mitchell McElree

Since Specialization
Citations

This map shows the geographic impact of Ian Mitchell McElree's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian Mitchell McElree with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian Mitchell McElree more than expected).

Fields of papers citing papers by Ian Mitchell McElree

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian Mitchell McElree. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian Mitchell McElree. The network helps show where Ian Mitchell McElree may publish in the future.

Co-authors

The 25 scholars most cited alongside Ian Mitchell McElree, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ian Mitchell McElree Line = papers co-authored together Ian Mitchell McElree links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 34 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non–Muscle-Invasive Bladder Cancer
JAMA Network Open ·Ian Mitchell McElree, Ryan L. Steinberg, Sarah L. Mott, Michael A. O’Donnell, Vignesh T. Packiam
Hit paper breakdown →		202379
2
Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer
The Journal of Urology ·Ian Mitchell McElree, Ryan L. Steinberg, Alex C. Martin, Jordan Richards, Sarah L. Mott, Paul Thomas Gellhaus, Kenneth Gerard Nepple, Michael A. O’Donnell
202252
3
Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer
Urologic Oncology Seminars and Original Investigations ·Phani T. Chevuru, Ian Mitchell McElree, Sarah L. Mott, Ryan L. Steinberg, Michael A. O’Donnell, Vignesh T. Packiam
202247
4
Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder Cancer
European Urology Oncology ·Wei Shen Tan, Ian Mitchell McElree, Facundo Davaro, Ryan L. Steinberg, Kelly K. Bree, Neema Navai, Colin P. Dinney, Michael A. O’Donnell
202332
5
Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer
British Journal of Urology ·Jacob I. Taylor, Ashish M. Kamat, Michael A. O’Donnell, Drupad Annapureddy, Jeffrey M. Howard, Wei Shen Tan, Ian Mitchell McElree, Facundo Davaro
202417
6
Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment of Non–Muscle-Invasive Bladder Cancer
The Journal of Urology ·Ian Mitchell McElree, Vignesh T. Packiam, Ryan L. Steinberg, Sarah L. Mott, Paul Thomas Gellhaus, Kenneth Gerard Nepple, Michael A. O’Donnell
202216
7
Sequential intravesical gemcitabine and docetaxel for treatment-naïve and previously treated intermediate-risk nonmuscle invasive bladder cancer
Urologic Oncology Seminars and Original Investigations ·Ian Mitchell McElree, Joanna Orzeł, Reid Stubbee, Ryan L. Steinberg, Sarah L. Mott, Michael A. O’Donnell, Vignesh T. Packiam
202314
8
Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now?
Expert Opinion on Pharmacotherapy ·Mohamad Abou Chakra, Vignesh T. Packiam, Igor Duquesne, Michaël Peyromaure, Ian Mitchell McElree, Michael A. O’Donnell
202413
9
Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin–Unresponsive Non–Muscle Invasive Bladder Cancer
European Urology Oncology ·Jacob I. Taylor, Ashish M. Kamat, Drupad Annapureddy, Zine-Eddine Khene, Jeffrey T. Howard, Wei Shen Tan, Ian Mitchell McElree, Davaro Facundo
202410
10
Sequential Endoluminal Gemcitabine and Cabazitaxel with Intravenous Pembrolizumab as a Bladder-Preserving Strategy for Docetaxel-Unresponsive Non-Muscle Invasive Urothelial Carcinoma Following Transurethral Resection of Bladder Tumor
Cancers ·Ian Mitchell McElree, Vignesh T. Packiam, Ryan L. Steinberg, Helen Y. Hougen, Sarah L. Mott, Mohamad Abou Chakra, Yousef Zakharia, Michael A. O’Donnell
20247
11
Alternative instillation techniques of sequential intravesical gemcitabine and docetaxel for non‐muscle‐invasive bladder cancer
British Journal of Urology ·Ian Mitchell McElree, Sarah L. Mott, Michael A. O’Donnell, Vignesh T. Packiam
20236
12
Sequential Endoluminal Doxorubicin and Gemcitabine Alternating Weekly with Sequential Mitomycin and Docetaxel for Recurrent Non-Muscle Invasive Urothelial Carcinoma
Cancers ·Ian Mitchell McElree, Vignesh T. Packiam, Ryan L. Steinberg, Helen Y. Hougen, Mohamad Abou Chakra, Sarah L. Mott, Michael A. O’Donnell
20245
13
Sequential endoluminal gemcitabine and docetaxel for the treatment of clinically non-invasive high-grade upper tract urothelial carcinoma
Urologic Oncology Seminars and Original Investigations ·Ian Mitchell McElree, Alex C. Belzer, Sarah L. Mott, Vignesh T. Packiam, Michael A. O’Donnell, Ryan L. Steinberg
20234
14
Early experience with sequential intravesical gemcitabine and docetaxel for micropapillary variant non-muscle invasive bladder cancer
Urologic Oncology Seminars and Original Investigations ·Mohamad Abou Chakra, Ian Mitchell McElree, Vignesh T. Packiam, Sarah L. Mott, Michael A. O’Donnell
20244
15
An update on the use of stem cell therapy for erectile dysfunction
Asian journal of urology ·Mohamad Abou Chakra, Hugo Bailly, Fabian Klampke, Johann Boaz, Mouatasem Jida, Ahmad Abou Yassine, Ian Mitchell McElree, Mohamad Moussa
20243
16
Presence of an Artificial Intelligence–powered Predictive Biomarker Is Associated with a Poor Response to Intravesical Bacillus Calmette-Guerin but Not to Intravesical Sequential Gemcitabine/Docetaxel in Patients with High-grade Non–muscle-invasive Bladder Cancer
European Urology Oncology ·Vignesh T. Packiam, Ian Mitchell McElree, Saum B. Ghodoussipour, Vivek U. Nimgaonkar, Viswesh Krishna, Joon Kyung Kim, Derek B. Allison, Jordan R. Richards
20253
17
Multi-institutional feasibility and safety outcomes of retroperitoneal robot-assisted partial nephrectomy in morbidly obese patients
Translational Andrology and Urology ·Thomas E. Stout, Ian Mitchell McElree, Aaron Smith, Goran Rac, Hiten Dilip Patel, Gopal Nand Gupta, Paul Thomas Gellhaus
20232
18
Two novel forms of ERG oscillation in Drosophila : age and activity dependence
Journal of Neurogenetics ·Atsushi Ueda, Scott Woods, Ian Mitchell McElree, Tristan C. D. G. O’Harrow, Casey Inman, Savantha Thenuwara, Muhammad Tariq Aftab, Atulya Iyengar
20182
19
ONCOLOGIC OUTCOMES OF BLADDER-SPARING MANAGEMENT FOR HIGH-GRADE NON-INVASIVE UROTHELIAL CARCINOMA OF THE PROSTATIC URETHRA
Urologic Oncology Seminars and Original Investigations ·Alexander C. Martin, Ian Mitchell McElree, Sarah L. Mott, Jordan R. Richards, Reid A. Stubbee, Ryan L. Steinberg, Michael A. O’Donnell, Vignesh T. Packiam
20242
20
Sequential endoluminal gemcitabine and docetaxel vs. Bacillus Calmette–Guérin for the treatment of upper tract carcinoma in situ
Urologic Oncology Seminars and Original Investigations ·Ian Mitchell McElree, Sarah L. Mott, Helen Y. Hougen, Vignesh T. Packiam, Michael A. O’Donnell, Ryan L. Steinberg
20242

About Ian Mitchell McElree

Ian Mitchell McElree is a scholar working on Surgery, Urology, Speech and Hearing, Hepatology and Psychiatry and Mental health, having authored 34 papers that have together received 331 indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (30 papers), Urinary and Genital Oncology Studies (11 papers), Urological Disorders and Treatments (4 papers), Epigenetics and DNA Methylation (2 papers), Colorectal Cancer Screening and Detection (1 paper), Infectious Disease Case Reports and Treatments (1 paper), Adolescent and Pediatric Healthcare (1 paper) and Esophageal Cancer Research and Treatment (1 paper). The work is most often cited by research in Surgery (306 citations), Urology (34 citations), Hepatology (5 citations), Pulmonary and Respiratory Medicine (20 citations) and Oncology (15 citations). Ian Mitchell McElree has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include Michael A. O’Donnell, Vignesh T. Packiam, Ryan L. Steinberg, Sarah L. Mott, Kenneth Gerard Nepple, Paul Thomas Gellhaus, Mohamad Abou Chakra, Neema Navai, Facundo Davaro and Kelly K. Bree. Their work appears in journals such as Urologic Oncology Seminars and Original Investigations, British Journal of Urology, European Urology Oncology, The Journal of Urology and Cancers.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fernando Álvarez LozanoBreakdown of academic impact, for papers by Philipp SpiegelhalderBreakdown of academic impact, for papers by Benjamin PradereBreakdown of academic impact, for papers by Júlia AumatellBreakdown of academic impact, for papers by Viveka StröckBreakdown of academic impact, for papers by Vianney BouyguesBreakdown of academic impact, for papers by George ManagadzeBreakdown of academic impact, for papers by A.R. AzzouziBreakdown of academic impact, for papers by Andrea MinerviniBreakdown of academic impact, for papers by William E. Osai